Daily Judi

Daily Judi: Friday, September 9, 2022

Every day we scan the headlines for the best items that engage the clinical trial ecosystem, workflow solutions, and more—all the latest news you need to know. Here are today's stories:

The National Institutes of Health announced a clinical trial evaluating a monkeypox vaccine and ways to increase available doses. The trial is now enrolling adult volunteers at eight sights across the United States, including Boston's Brigham and Women’s Hospital, Vanderbilt University, and the University of California, San Diego.

A new report from GSK, formerly GlaxoSmithKline, finds a significant percentage of those with asthma are unhappy with the management of the condition. (Fierce Pharma)

Nature investigates what the world's scientists are learning about the costs and benefits of COVID-19 lockdown measures.

The CNS Summit 2022 will be held on November 17–20, in Boca Raton, Florida. Created as "a community of innovators and industry leaders who are not afraid to challenge the status quo," CNS was founded in 2009 to advance clinical development, focused on collaboration and innovation. Team Judi will be there!

We hope to see you next week, September 13-14, in Boston, for DPHARM: Disruptive Innovations to Advance Clinical Trials, walking distance from our North End headquarters.

Attending the annual conference of the Society for Clinical Data Management in San Antonio, Texas (SCDM2022)? Join AG Mednet's Abraham Gutman in a roundtable discussion on how imaging quality control automation improve endpoint data, Monday, September 12, 2022, 1:45 to 2:45 p.m.

Our Culture

“We work proactively with each client, analyzing our reports to make them work faster, to help make our client’s life better.”

                                            –Tim, Trial Delivery

About Judi

Judi empowers and enhances the world's clinical trial ecosystems. Our cloud-based platform has 110,000 users across 140 countries. We eliminate the chaos so clinical teams can focus on the patient, rather than the process. We are a SOC 2 Type II certified collaboration platform.

No tags found.

Stay up-to-date with whats happening

Some sub copy covering what weekly/monthly update sand news one can expect.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.